American Academy of Child & Adolescent Psychiatry

Triple-bead MAS improves ADHD symptoms in adults, data indicate

Triple-bead mixed amphetamine salts (MAS), an investigational formulation of MAS designed for once-daily dosing, significantly improves symptoms of attention-deficit/hyperactivity disorder in adults, according to findings from 2 Phase III trials.

The double-blind trials enrolled adults aged 18 to 55 years with ADHD. In ...[more]

MTA Cooperative Group uses 8-year MTA follow-up data to assess long-term outcomes in children with ADHD

Initial data from the Multimodal Treatment Study of Children with ADHD (MTA) provided information about the efficacy of different treatments and treatment combinations in pediatric attention-deficit/hyperactivity disorder. Now, with 8-year follow-up data available, the MTA offers insight into the long-term outcomes of ADHD, including ...[more]

Stigma associated with ADHD prevalent, may affect receptivity to treatment

The stigma surrounding attention-deficit/hyperactivity disorder is prevalent and may influence adolescent and caregiver treatment decisions, but clinicians can use this information to select the most appropriate treatment plan, a panel advised.

Several of the panel speakers focused on ADHD-related stigma and presented ...[more]

Triple-bead MAS improves ADHD symptoms in adults, data indicate

Triple-bead mixed amphetamine salts (MAS), an investigational formulation of MAS designed for once-daily dosing, significantly improves symptoms of attention-deficit/hyperactivity disorder in adults, according to findings from 2 Phase III trials.

The double-blind trials enrolled adults aged 18 to 55 years with ADHD. In ...[more]

MTA Cooperative Group uses 8-year MTA follow-up data to assess long-term outcomes in children with ADHD

Initial data from the Multimodal Treatment Study of Children with ADHD (MTA) provided information about the efficacy of different treatments and treatment combinations in pediatric attention-deficit/hyperactivity disorder. Now, with 8-year follow-up data available, the MTA offers insight into the long-term outcomes of ADHD, including ...[more]

Guanfacine XR does not affect daytime sleepiness, increases evening sleepiness in children, adolescents with ADHD, safety analysis shows

Phase II data confirm the safety profile of guanfacine extended release (XR) in children and adolescents with attention-deficit/hyperactivity disorder and suggest that the drug may increase evening sleepiness in these patients, but it does not increase daytime sleepiness in the classroom.

The current analysis was ...[more]

Dexmethylphenidate extended release at daily doses as high as 30 mg yields improvements in teacher-rated reports of children with ADHD

Dexmethylphenidate extended release is effective in treating children with attention-deficit/hyperactivity disorder, according to the results of a double-blind, fixed-dose titration trial.

Researchers randomized 253 pediatric patients aged 6 to 12 years with ADHD to 1 of 4 treatment arms.  Following a washout period, ...[more]

Childhood ADHD associated with functional deficits in young adulthood, findings suggest

Children with attention-deficit/hyperactivity disorder may be more likely than children without ADHD to experience specific functional deficits in young adulthood, data suggest.

The authors of the current analysis noted that recent research has begun to investigate outcomes in ADHD other than those related strictly to ...[more]

Lisdexamfetamine beneficial for adults with ADHD, new data indicate

Adult patients with attention-deficit/hyperactivity disorder demonstrate significant improvements in symptom control within a week of taking lisdexamfetamine, Phase III trial data show.

The double-blind, dose-escalation study included 420 adults aged 18 to 55 years who met DSM-IV-TR criteria for ADHD and whose diagnosis ...[more]

ADHD, medication use in children associated with emotional strain, poor health status among caregivers

Caregivers of children with attention-deficit/hyperactivity disorder--especially those of children who are taking drug therapy--experience significantly more emotional strain and poorer physical and mental health status than do caregivers of children without ADHD, a study found.

For this investigation, 2,036 caregivers ...[more]

Choosing best therapy for ADHD difficult, requires consideration of several factors

Clinicians encounter several challenges when selecting which treatment may be optimal for patients with attention-deficit/hyperactivity disorder, but more research and new approaches could provide some guidance, according to several experts.

"I think what we want to highlight is that there are multiple factors that go ...[more]

Triple-bead mixed amphetamine salts improves ADHD symptoms in adolescents during 16-hour treatment period, Phase II data indicate

Once-daily dosing with triple-bead mixed amphetamine salts (triple-bead MAS), an investigational treatment for attention-deficit/hyperactivity disorder, seems to improve ADHD symptoms in adolescents relative to placebo and demonstrates efficacy throughout a 16-hour treatment period, according to Phase II findings.

...[more]

Research suggests atomoxetine does not increase smoking in adult smokers with ADHD, but smoking status may predict response to treatment

Among adult smokers with attention-deficit/hyperactivity disorder, atomoxetine does not increase cigarette smoking, according to an analysis of Phase IV data. Additional findings suggest smoking status may affect the likelihood of treatment response in adults with ADHD.

The double-blind study included 218 adults aged 18 ...[more]

OROS methylphenidate safely treats adult ADHD, trials show

OROS methylphenidate is a safe and effective treatment for adult attention-deficit/hyperactivity disorder, according to an analysis of interim data from a long-term, open-label safety trial and data from a randomized, placebo-controlled, dose-titration study.

In the open-label safety study, OROS methylphenidate was ...[more]

Guanfacine XR does not affect daytime sleepiness, increases evening sleepiness in children, adolescents with ADHD, safety analysis shows

Phase II data confirm the safety profile of guanfacine extended release (XR) in children and adolescents with attention-deficit/hyperactivity disorder and suggest that the drug may increase evening sleepiness in these patients, but it does not increase daytime sleepiness in the classroom.

The current analysis was ...[more]

Dexmethylphenidate extended release at daily doses as high as 30 mg yields improvements in teacher-rated reports of children with ADHD

Dexmethylphenidate extended release is effective in treating children with attention-deficit/hyperactivity disorder, according to the results of a double-blind, fixed-dose titration trial.

Researchers randomized 253 pediatric patients aged 6 to 12 years with ADHD to 1 of 4 treatment arms.  Following a washout period, ...[more]

Childhood ADHD associated with functional deficits in young adulthood, findings suggest

Children with attention-deficit/hyperactivity disorder may be more likely than children without ADHD to experience specific functional deficits in young adulthood, data suggest.

The authors of the current analysis noted that recent research has begun to investigate outcomes in ADHD other than those related strictly to ...[more]

Lisdexamfetamine beneficial for adults with ADHD, new data indicate

Adult patients with attention-deficit/hyperactivity disorder demonstrate significant improvements in symptom control within a week of taking lisdexamfetamine, Phase III trial data show.

The double-blind, dose-escalation study included 420 adults aged 18 to 55 years who met DSM-IV-TR criteria for ADHD and whose diagnosis ...[more]

ADHD, medication use in children associated with emotional strain, poor health status among caregivers

Caregivers of children with attention-deficit/hyperactivity disorder--especially those of children who are taking drug therapy--experience significantly more emotional strain and poorer physical and mental health status than do caregivers of children without ADHD, a study found.

For this investigation, 2,036 caregivers ...[more]

Choosing best therapy for ADHD difficult, requires consideration of several factors

Clinicians encounter several challenges when selecting which treatment may be optimal for patients with attention-deficit/hyperactivity disorder, but more research and new approaches could provide some guidance, according to several experts.

"I think what we want to highlight is that there are multiple factors that go ...[more]

Triple-bead mixed amphetamine salts improves ADHD symptoms in adolescents during 16-hour treatment period, Phase II data indicate

Once-daily dosing with triple-bead mixed amphetamine salts (triple-bead MAS), an investigational treatment for attention-deficit/hyperactivity disorder, seems to improve ADHD symptoms in adolescents relative to placebo and demonstrates efficacy throughout a 16-hour treatment period, according to Phase II findings.

...[more]

Research suggests atomoxetine does not increase smoking in adult smokers with ADHD, but smoking status may predict response to treatment

Among adult smokers with attention-deficit/hyperactivity disorder, atomoxetine does not increase cigarette smoking, according to an analysis of Phase IV data. Additional findings suggest smoking status may affect the likelihood of treatment response in adults with ADHD.

The double-blind study included 218 adults aged 18 ...[more]

OROS methylphenidate safely treats adult ADHD, trials show

OROS methylphenidate is a safe and effective treatment for adult attention-deficit/hyperactivity disorder, according to an analysis of interim data from a long-term, open-label safety trial and data from a randomized, placebo-controlled, dose-titration study.

In the open-label safety study, OROS methylphenidate was ...[more]